check_circleStudy Completed
Acute Bacterial Sinusitis
Bayer Identifier:
12803
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Treatment of patients with acute sinusitis
Trial purpose
For each patient, an initial visit and at least one follow-up visit at the end of treatment should be documented by the treating physician in the case report form.
Key Participants Requirements
Sex
BothAge
NaN - N/ATrial summary
Enrollment Goal
6777Trial Dates
March 2007 - December 2008Phase
N/ACould I Receive a placebo
NoProducts
Avelox (Moxifloxacin hydrochloride, BAY12-8039)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Many Locations, United Arab Emirates | |
Completed | Many Locations, China | |
Completed | Many Locations, Kuwait | |
Completed | Many Locations, Lebanon | |
Completed | Many Locations, Malaysia | |
Completed | Many Locations, Romania | |
Completed | Many Locations, Singapore | |
Completed | Many Locations, Yemen | |
Completed | Many Locations, Germany | |
Completed | Many Locations, Austria | |
Completed | Many Locations, Bahrain | |
Completed | Many Locations, Egypt | |
Completed | Many Locations, France | |
Completed | Many Locations, Indonesia | |
Completed | Many Locations, Jordan | |
Completed | Many Locations, Netherlands | |
Completed | Many Locations, Philippines | |
Completed | Many Locations, Pakistan | |
Completed | Many Locations, Saudi Arabia |
Primary Outcome
- Evaluation of potential benefits of an antibacterial therapy with Avelox® (moxifloxacin) in patients with acute bacterial sinusitis to whom this treatment was prescribed. Especially the time to improvement and resolution of clinical signs and symptoms ofdate_rangeTime Frame:Documentation at baseline and at at least one follow-up visit. Evaluation of therapy outcome at last follow-up visit at end of therapy (approximately after 7 days).enhanced_encryptionnoSafety Issue:
Secondary Outcome
- Evaluation of tolerability and safety of Avalox® in daily practice were investigated.date_rangeTime Frame:Evaluation of therapy outcome at last follow-up visit at end of therapy (approximately after 7 days).enhanced_encryptionyesSafety Issue:
- Patient characteristics in acute bacterial sinusitisdate_rangeTime Frame:Documentation at baseline visit.enhanced_encryptionnoSafety Issue:
- History and frequency of sinusitis episodesdate_rangeTime Frame:Documentation at baseline visit.enhanced_encryptionnoSafety Issue:
- Diagnostic procedures and therapeutic options chosen by physicians in daily practicedate_rangeTime Frame:Documentation at baseline visit.enhanced_encryptionnoSafety Issue:
Trial design
Trial Type
ObservationalIntervention Type
DrugTrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A